CymaBay Therapeutics
7999 Gateway Blvd.
Suite 130
Newark
California
94560
United States
Tel: 510-293-8800
Website: http://www.cymabay.com/
Email: info@cymabay.com
About CymaBay Therapeutics
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist, currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with non-alcoholic steatohepatitis (NASH).
172 articles about CymaBay Therapeutics
-
CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis
3/4/2024
CymaBay Therapeutics, Inc. announced that the Marketing Authorization Application for seladelpar, for the treatment of primary biliary cholangitis including pruritus in adults without cirrhosis or with compensated cirrhosis who are inadequate responders or intolerant to ursodeoxycholic acid), has been validated and will now be reviewed by the European Medicines Agency.
-
CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
2/28/2024
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the year and fourth quarter ended December 31, 2023.
-
After a slow start to 2023 in an uncertain economic climate, biopharma mergers and acquisitions are on the rise.
-
The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis
2/21/2024
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced that The New England Journal of Medicine (NEJM) has published detailed results from the RESPONSE Phase 3 trial evaluating seladelpar, an investigational agent, and the only potent, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist or delpar, being studied in adults with primary biliary cholangitis (PBC).
-
Mergers and acquisitions are trending upward as Novo Nordisk, Gilead, and Johnson & Johnson kick off the year with big deals. AI and other scientific advances will likely be the focus of M&As yet to come.
-
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 20, 2024
2/20/2024
CymaBay Therapeutics, Inc. announced the grant of inducement awards to three employees on February 16, 2024 in connection with the employees’ commencement of employment at CymaBay.
-
CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis
2/12/2024
CymaBay Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for seladelpar, an investigational treatment for the management of primary biliary cholangitis (PBC) including pruritus in adults without cirrhosis or with compensated cirrhosis (Child Pugh A) who are inadequate responders or intolerant to ursodeoxycholic acid.
-
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
2/12/2024
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics.
-
Gilead Sciences announced Monday it will purchase CymaBay Therapeutics and its investigational treatment seladelpar for primary biliary cholangitis, a type of liver disease that causes bile-duct damage.
-
CymaBay Therapeutics to Participate in Upcoming Investment Conferences
1/31/2024
CymaBay Therapeutics, Inc. today announced that members of its management team will participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference, February 7-8, in New York, NY.
-
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 16, 2024
1/16/2024
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced the grant of inducement awards to two employees on January 12, 2024 in connection with the employees’ commencement of employment at CymaBay.
-
New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement in Primary Biliary Cholangitis in Phase 3 Post-Hoc Analysis of CymaBay's Seladelpar
1/3/2024
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced the first published findings demonstrating the impact of seladelpar on serum interleukin-31 (IL-31) levels and its correlation with pruritus improvement in people with primary biliary cholangitis (PBC).
-
CymaBay Therapeutics to Present at the 42nd Annual JP Morgan Healthcare Conference 2024
1/2/2024
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced that its President and Chief Executive Officer, Sujal Shah, will present at the upcoming 42nd Annual JP Morgan Healthcare Conference taking place January 8 -11 in San Francisco, California.
-
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 18, 2023
12/18/2023
CymaBay Therapeutics, Inc. announced the grant of inducement awards to four employees on December 15, 2023 in connection with the employees’ commencement of employment at CymaBay.
-
CymaBay Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis
12/15/2023
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for investigational treatment, seladelpar, for the management of primary biliary cholangitis, including pruritus in adults without cirrhosis or with compensated cirrhosis (Child Pugh A) who are inadequate responders or intolerant to ursodeoxycholic acid (UDCA).
-
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 17, 2023
11/17/2023
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced the grant of inducement awards to five employees on November 15, 2023 in connection with the employees’ commencement of employment at CymaBay.
-
CymaBay Announces an Oral Presentation of Seladelpar Phase 3 Pivotal Results in Primary Biliary Cholangitis at the Late Breaker Session of the Liver Meeting®
11/13/2023
CymaBay Therapeutics, Inc. today announced that the results from its RESPONSE Phase 3 registration study evaluating seladelpar, a potent, selective, orally-active delpar, or PPAR𝛿 agonist, in adult patients with primary biliary cholangitis (PBC) will be featured as an oral presentation in today's Late Breaker Session of the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting® 2023 in Boston, Massachusetts.
-
CymaBay Reports Third Quarter and Nine Months Ended September 30, 2023 Financial Results and Provides Corporate Update
11/7/2023
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced corporate updates and financial results for the third quarter ended September 30, 2023.
-
CymaBay Therapeutics to Present at Upcoming Investment Conferences
11/6/2023
CymaBay Therapeutics, Inc. today announced that members of its management team will participate in the UBS Biopharma Conference, November 8-9th in Miami Beach, FL.
-
CymaBay Announces Publication of Two-year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary Cholangitis
11/1/2023
CymaBay Therapeutics, Inc., a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, announced that two-year safety and efficacy results of seladelpar for primary biliary cholangitis have been published in Alimentary Pharmacology & Therapeutics.